Omada Health Schedules Annual Meeting, Details Executive Compensation and Key Related-Party Transactions

summarizeSummary

Omada Health filed its definitive proxy statement for the June 16, 2026 Annual Meeting, outlining routine proposals, significant executive compensation increases for 2025, and material commercial agreements with a major shareholder, Cigna.

check_boxKey Events

• Annual Meeting Scheduled

  Omada Health will hold its 2026 Annual Meeting of Stockholders virtually on June 16, 2026, for shareholders of record as of April 20, 2026.

• Director Elections & Auditor Ratification

  Shareholders will vote on the re-election of Sean Duffy (CEO) and Trevor Fetter as Class I Directors and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026.

• Executive Compensation Details

  Named executive officers saw significant increases in total compensation for 2025, primarily due to substantial stock awards granted in connection with the company's initial public offering. CEO Sean Duffy's total compensation was $4.7 million.

• Material Related-Party Transactions

  The company disclosed significant commercial arrangements with Cigna and its affiliates, a greater than 5% beneficial owner. These agreements generated $157.6 million in payments to Omada Health in 2025 and $58.1 million year-to-date in 2026.

auto_awesomeAnalysis

This definitive proxy statement provides comprehensive details for Omada Health's upcoming annual shareholder meeting. While the proposals for director elections and auditor ratification are routine, the filing highlights substantial executive compensation for 2025, driven by significant stock awards following the company's initial public offering. A key disclosure is the material commercial relationship with Cigna and its affiliates, a greater than 5% beneficial owner, which generated $157.6 million in payments to Omada Health in 2025. This indicates a significant business dependency on a related party. Additionally, the company's equity compensation plans include evergreen provisions allowing for potential annual dilution of approximately 6% of outstanding shares, which investors should monitor.